Sign in
Taking people in United StatesEarly phase 1

Testosterone nasal gel and nerve function in men with spinal cord injury

Tests a single nasal testosterone dose on nerve function in men with spinal cord injury.

Key facts

Who runs it
VA Office of Research and Development
Where
The Bronx, United StatesSee the site
Trial code
Registry title
Testosterone and Neural Function in Men With Spinal Cord Injury
Status
Recruiting
Phase
Early phase 1
People taking part
15 people, planned
Started
1 Apr 2024
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Natesto testosterone intranasal gel
  • Ayr Saline Nasal Gel
Record updated
6 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with a spinal cord injury and low testosterone. It tests how one dose of testosterone nasal gel affects nerve, movement and heart rate or blood pressure control.

Age
18 Years to 80 Years
Sex
Men only
Disease stage
Spinal cord injury from an accident or another cause, more than 12 months ago. AIS grade A, B, C or D.
Earlier treatment
You cannot currently be on drug treatment for low testosterone. Your prescription medicines must have been stable for at least 30 days.
Biomarker or test result
Low testosterone with signs or symptoms: total T <300 ng/dL, free T <46 pg/mL, or bioavailable T <110 ng/dL.

Main reasons for not taking part

  • Many past seizures, or medicines that make seizures more likely, such as bupropion
  • Needing a ventilator, or an open tracheostomy
  • Other nerve or brain disorders, moderate or severe head injury, or stroke
  • Serious heart disease or heart rhythm conduction disease
  • Implanted devices like pacemakers, nerve stimulators or cochlear implants

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Male
  • Hypogonadal (Serum Total T <300 nanograms per deciliter (ng/dL), Free T <46 picograms per milliliter (pg/mL), or bioavailable T <110 ng/dL) with signs/symptoms of hypogonadism
  • Traumatic or non-traumatic spinal cord injury (SCI)
  • Time since injury (TSI) more than 12 months
  • American Spinal Injury Association (ASIA) Injury classification Scale (AIS) A, B, C, or D
  • Stable prescription medication regimen for at least 30 days
  • Not currently receiving pharmacological treatment for hypogonadism
  • Must be able to commit to study requirements of 3 visits within a 30-day period
  • Provide informed consent

Who cannot take part

  • Currently receiving treatment for hypogonadism
  • Extensive history of seizures
  • History of neurologic disorder other than spinal cord injury (SCI)
  • History of moderate or severe head trauma
  • History of allergy, hypersensitivity, or other significant adverse reaction to testosterone replacement therapy
  • Significant cardiovascular disease or cardiac conduction disease
  • Active psychological disorder
  • Moderate or severe brain injury, stroke, tumor, multiple sclerosis, or abscess
  • Active infection
  • Recent history (within past 6 months) of recurrent autonomic dysreflexia, defined as a syndrome of sudden rise in systolic pressure greater than 20 mm Hg or diastolic pressure greater than 10 millimeters of mercury (mm Hg), without rise in heart rate, accompanied by symptoms such as headache, facial flushing, sweating, nasal congestion, and blurry vision (this will be closely monitored during all screening and testing procedures)
  • History of implanted devices with electromagnetic properties: brain/spine/nerve stimulators, aneurysm clips, ferromagnetic metallic implants in the head (except for inside mouth); cochlear implants; cardiac pacemaker/defibrillator; intracardiac lines; currently increased intracranial pressure; or other contraindications to brain or spine stimulation
  • Use of medications that significantly lower seizure threshold, such as amphetamines, neuroleptics, dalfampridine, and bupropion
  • Ventilator dependence or patent tracheostomy site
  • Recent history (within 3 months) of substance abuse
  • Pressures sores stage 3 or greater
  • Frequent severe migraines

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

  • James J. Peters VA Medical Center, Bronx, NYThe Bronx, United StatesContact: Dylan C Arnero, MA BATaking people

About the trial

What the trial wants to find out

Spinal cord injury (SCI) disrupts the nerves controlling movement, along with those that regulate functions like heart rate and blood pressure (known as the autonomic nervous system, or ANS). Testosterone (T) plays a significant role in brain health and ANS reflex function in non-neurologically impaired men. However, little is known about the relationships between T, nerve function, and ANS dysfunction after SCI. Interestingly, up to 60% of men with SCI exhibit persistently low T concentrations, which may worsen nerve and ANS dysfunction. In uninjured eugonadal people (normal physiologic range of serum T concentrations), a single pharmacologic dose of intranasal T has been shown to quickly improve nerve function, but no study has evaluated if T administration alters nerve and ANS function in men with SCI. Herein, the investigators will conduct the first study to test how a single dose of intranasal T impacts motor and ANS function in this population.

The 2 groups in the trial

  • PlaceboPlacebo, for comparison

    Participant-blinded (Ayr Saline Gel)

    Treatment: Ayr Saline Nasal Gel

  • Intranasal TRTExisting treatment, for comparison

    Participant-blinded (11 mg of Natesto)

    Treatment: Natesto testosterone intranasal gel

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Role of Androgens in Neurophysiological and Autonomic Function in Male Veterans With Spinal Cord Injury
Plain-language title
Testosterone nasal gel and nerve function in men with spinal cord injuryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06130449, who can take part
Record updated
6 October 2026